9Jin L,Jin H,Zhang G,et al.Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with cumbrokinase.Clin Hemorheol Microcirc,2000,23 (2-4):213-218.
10Parving HH,Lehnert H,Broahnner J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med,2001,345(12):870-878.
1Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) [ J ]. Clin J Am Soc Nephrol, 2009,4 ( 2 ) : 361-368.
2Overgaard AJ,McGuire JN,Hovind P,et al.Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1diabetic patients[J].J Diabetes Complications,2013,27(1):59-63.
3Brownlee M.Biochemistry and molecular cell biology of diabetic complications[J].Nature,2001,414(6865):813-820.
4Le DS,Miles R,Savage PJ,et al.The association of plasma fibri-nogen concentration with diabetic microvascular complications in young adults with early-onset of type 2diabetes[J].Diabetes Res Clin Pract,2008,82(3):317-323.
5Tsun JG,Shiu SW,Wong Y,et al.Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus[J].Atherosclerosis,2013,231(2):405-410.
